Applied Molecular Transport Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
AMTI
- Share Price
-
$0.21
- (As of Friday Closing)
Applied Molecular Transport General Information
Description
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Contact Information
- 325 Sharon Park Drive
- Suite 1001
- Menlo Park, CA 94025
- United States
Applied Molecular Transport Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.21 | $0.19 | $0.13 - $1.31 | $8.61M | 41.8M | 1.23M | -$1.90 |
Applied Molecular Transport Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (14,478) | (23,113) | 367,769 | 926,708 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (75,075) | (124,095) | (97,662) | (64,951) |
| Net Income | (74,786) | (126,325) | (100,287) | (66,564) |
| Total Assets | 20,015 | 107,446 | 214,038 | 140,183 |
| Total Debt | 1,353 | 36,121 | 39,773 | 636 |
Applied Molecular Transport Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Applied Molecular Transport Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Applied Molecular Transport Comparisons
Industry
Financing
Details
000000
000000
Applied Molecular Transport Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | 000 | 00000 | 00000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000000 | 00000 |
| 00000 & 00. | Corporation | Rahway, NJ | 00000 | 000.00 | 000000000 | 000.00 |
| 0000000 000000 000 | Venture Capital-Backed | Titusville, NJ | 00000 | 000000 - 000 |
Applied Molecular Transport Patents
Applied Molecular Transport Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020331939-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | 00000000000 | |
| CA-3150859-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | 00000000000 | |
| EP-3844169-A1 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | 00000000000 | |
| EP-3844169-A4 | Compositions, formulations, and interleukin production and purification | Pending | 16-Aug-2019 | 00000000000 | 0 |
| US-11466067-B2 | Compositions, formulations and interleukin production and purification | Active | 16-Aug-2019 | C07K14/5428 | 000 |
Applied Molecular Transport Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Shawn Cross | Chief Executive Officer & Chairman | ||
| Brandon Hants | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
Applied Molecular Transport Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aaron VanDevender Ph.D | Applied Molecular Transport | Board Member | 000 0000 |
| Charlene Banard | Applied Molecular Transport | Board Member | 000 0000 |
| John Smither | Self | Board Member | 000 0000 |
| Randall Mrsny Ph.D | Applied Molecular Transport | Co-Founder | 000 0000 |
| Shawn Cross | Applied Molecular Transport | Chief Executive Officer & Chairman | 000 0000 |
Applied Molecular Transport Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Applied Molecular Transport Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Applied Molecular Transport ESG
Risk Overview
Risk Rating
Updated October, 05, 2022
29.62 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile
Biotechnology
Subindustry
00 of 465
Rank
Percentile
